Cardiogenics Holdings Stock Performance
| CGNH Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and CardioGenics Holdings are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days CardioGenics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, CardioGenics Holdings is not utilizing all of its potentials. The recent stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Total Cashflows From Investing Activities | -2057.00 |
CardioGenics |
CardioGenics Holdings Relative Risk vs. Return Landscape
If you would invest 0.01 in CardioGenics Holdings on December 27, 2024 and sell it today you would earn a total of 0.00 from holding CardioGenics Holdings or generate 0.0% return on investment over 90 days. CardioGenics Holdings is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than CardioGenics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CardioGenics Holdings Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CardioGenics Holdings' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as CardioGenics Holdings, and traders can use it to determine the average amount a CardioGenics Holdings' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CGNH |
Based on monthly moving average CardioGenics Holdings is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CardioGenics Holdings by adding CardioGenics Holdings to a well-diversified portfolio.
CardioGenics Holdings Fundamentals Growth
CardioGenics Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of CardioGenics Holdings, and CardioGenics Holdings fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CardioGenics Pink Sheet performance.
| Return On Asset | -1.15 | |||
| Current Valuation | 2.3 M | |||
| Shares Outstanding | 96.05 M | |||
| Price To Earning | (0.67) X | |||
| Price To Sales | 80,069 X | |||
| EBITDA | (753.55 K) | |||
| Cash And Equivalents | 96.81 K | |||
| Book Value Per Share | (0.01) X | |||
| Cash Flow From Operations | (606.64 K) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 231.93 K | |||
| Retained Earnings | (49.68 M) | |||
| Current Asset | 385 K | |||
| Current Liabilities | 2.35 M | |||
About CardioGenics Holdings Performance
By evaluating CardioGenics Holdings' fundamental ratios, stakeholders can gain valuable insights into CardioGenics Holdings' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if CardioGenics Holdings has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if CardioGenics Holdings has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
CardioGenics Holdings Inc. engages in the development and commercialization of diagnostic test products for the in vitro diagnostics testing market in the United States, Canada, Europe, and internationally. The company was founded in 1997 and is headquartered in Mississauga, Canada. Cardiogenics Holdings operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about CardioGenics Holdings performance evaluation
Checking the ongoing alerts about CardioGenics Holdings for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for CardioGenics Holdings help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CardioGenics Holdings generated a negative expected return over the last 90 days | |
| CardioGenics Holdings has some characteristics of a very speculative penny stock | |
| CardioGenics Holdings has a very high chance of going through financial distress in the upcoming years | |
| The company has a current ratio of 0.16, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist CardioGenics Holdings until it has trouble settling it off, either with new capital or with free cash flow. So, CardioGenics Holdings' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CardioGenics Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CardioGenics to invest in growth at high rates of return. When we think about CardioGenics Holdings' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (1.92 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CardioGenics Holdings currently holds about 96.81 K in cash with (606.64 K) of positive cash flow from operations. |
- Analyzing CardioGenics Holdings' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CardioGenics Holdings' stock is overvalued or undervalued compared to its peers.
- Examining CardioGenics Holdings' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CardioGenics Holdings' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CardioGenics Holdings' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CardioGenics Holdings' pink sheet. These opinions can provide insight into CardioGenics Holdings' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for CardioGenics Pink Sheet analysis
When running CardioGenics Holdings' price analysis, check to measure CardioGenics Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CardioGenics Holdings is operating at the current time. Most of CardioGenics Holdings' value examination focuses on studying past and present price action to predict the probability of CardioGenics Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CardioGenics Holdings' price. Additionally, you may evaluate how the addition of CardioGenics Holdings to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |